Literature DB >> 17160711

Mechanisms of invasion and metastasis in human neuroblastoma.

Tasnim Ara1, Yves A DeClerck.   

Abstract

Neuroblastoma is the second most common solid tumor in children that is metastatic in 70% of patients at the time of diagnosis. The ability of neuroblastoma cells to colonize distant organs like the bone marrow and the bone is the result of close interactions between tumor cells and the microenvironment. Significant progress has been recently made in our understanding of the mechanisms that promote the colonization and invasion of the bone by neuroblastoma cells and these mechanisms are reviewed in this article. How this understanding is now allowing us to test new therapeutic agents specifically targeted at interfering with neuroblastoma metastasis is then discussed.

Entities:  

Mesh:

Year:  2006        PMID: 17160711     DOI: 10.1007/s10555-006-9028-9

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  37 in total

1.  Combined effects of curcumin and doxorubicin on cell death and cell migration of SH-SY5Y human neuroblastoma cells.

Authors:  Jirapat Namkaew; Thiranut Jaroonwitchawan; Narawadee Rujanapun; Jantip Saelee; Parinya Noisa
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-08-22       Impact factor: 2.416

2.  PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.

Authors:  Joanna E Gawecka; Dirk Geerts; Jan Koster; Maisel J Caliva; Florian J Sulzmaier; John Opoku-Ansah; Randal K Wada; André S Bachmann; Joe W Ramos
Journal:  Int J Cancer       Date:  2012-01-31       Impact factor: 7.396

3.  Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration.

Authors:  C M Fife; S M Sagnella; W S Teo; S T Po'uha; F L Byrne; Y Y C Yeap; D C H Ng; T P Davis; J A McCarroll; M Kavallaris
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

4.  HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.

Authors:  Linlin Zhang; Ningning Liu; Songbo Xie; Xianfei He; Jun Zhou; Min Liu; Dengwen Li
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

5.  Patterning N-type and S-type neuroblastoma cells with Pluronic F108 and ECM proteins.

Authors:  Joseph M Corey; Caitlyn C Gertz; Thomas J Sutton; Qiaoran Chen; Katherine B Mycek; Bor-Shuen Wang; Abbey A Martin; Sara L Johnson; Eva L Feldman
Journal:  J Biomed Mater Res A       Date:  2010-05       Impact factor: 4.396

6.  Cell adhesion molecules in metastatic neuroblastoma models.

Authors:  Nina Schwankhaus; Christina Gathmann; Daniel Wicklein; Kristoffer Riecken; Udo Schumacher; Ursula Valentiner
Journal:  Clin Exp Metastasis       Date:  2014-02-19       Impact factor: 5.150

7.  Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition.

Authors:  Kimiya Memarzadeh; David J Savage; Andrew J Bean
Journal:  Cancer Biol Ther       Date:  2019-09-01       Impact factor: 4.742

8.  Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models.

Authors:  Roberta Vitali; Camillo Mancini; Vincenzo Cesi; Barbara Tanno; Mariateresa Mancuso; Gianluca Bossi; Ying Zhang; Robert V Martinez; Bruno Calabretta; Carlo Dominici; Giuseppe Raschellà
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

9.  Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.

Authors:  Eva Villamón; Marta Piqueras; Carlos Mackintosh; Javier Alonso; Enrique de Alava; Samuel Navarro; Rosa Noguera
Journal:  Virchows Arch       Date:  2008-06-24       Impact factor: 4.064

10.  Identification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progression.

Authors:  Carine Nyalendo; Hervé Sartelet; Stéphane Barrette; Shigeru Ohta; Denis Gingras; Richard Béliveau
Journal:  BMC Cancer       Date:  2009-12-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.